Ayman Al Jurdi

7PUBLICATIONS
10CO-AUTHORS
Medical infection agents (incl. prions)Pharmaceutical delivery technologiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 14, 2026
Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia.

|Jun 13, 2024
Delayed-Release Budesonide in a Patient With Progressive IgA Nephropathy and Stage 4 Chronic Kidney Disease: A Case Report.

Zohreh Gholizadeh Ghozloujeh, Vinay Srinivasan, Ayman Al Jurdi

|Sep 02, 2023
Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis.

Ayman Al Jurdi, Christopher El Mouhayyar, Orhan Efe

|Jun 21, 2022
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.

Ayman Al Jurdi, Leela Morena, Mariesa Cote

Pageof 2

Frequent Collaborators

3 joint publications

Orhan Efe

2 joint publications

Harish Seethapathy

2 joint publications

Anushya Jeyabalan

1 joint publications

Jamil Azzi